Augmentation of NK cell activity in tissue specific sites by liposomes incorporating MTP-PE.
Liposomes incorporating a variety of immunomodulators have been shown to activate macrophages and monocytes for tumoricidal activity both in vivo and in vitro. We report that in addition to the activation of macrophages, the i.v. injection of liposomes (multilamellar vesicles) that have encapsulated muramyl tripeptide-phosphatidylethanolamine (MTP-PE) could also augment interstitial natural killer (NK) cell activity in the lung and the liver. In contrast, liposomes incorporating MTP-PE were unable to augment NK cell activity in the spleen, peripheral blood, or peritoneal cavity (after i.p. injection). In addition, liposomes did not augment splenic NK cell activity in vitro. This suggests that the augmentation of NK cell activity in the lungs and liver was not due to direct effects of the liposomes but may have been a secondary effect mediated by a monokine. The augmentation of pulmonary NK cell activity was paralleled by the nonspecific immunoprophylaxis of experimental pulmonary metastases. The augmented NK cell activity, as well as the enhanced nonspecific immunoprophylactic activity, was reduced by pretreatment of the mice with anti-asialo GM1 antiserum. Thus, the augmentation of organ-associated NK cell activity by liposomes incorporating MTP/PE plays a major role in the host's increased resistance to the formation of experimental metastases.
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives* / Q000276:immunology / Q000627:therapeutic use; D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D005354:Fibrosarcoma / Q000276:immunology; D007694:Killer Cells, Natural / Q000276:immunology*; D008081:Liposomes / Q000008:administration & dosage / Q000276:immunology*; D008099:Liver / Q000166:cytology; D008168:Lung / Q000166:cytology; D008175:Lung Neoplasms / Q000517:prevention & control / Q000556:secondary; D008223:Lymphoma / Q000276:immunology; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D010714:Phosphatidylethanolamines / Q000276:immunology* / Q000627:therapeutic use; D013154:Spleen / Q000166:cytology
D000276:Adjuvants, Immunologic; D008081:Liposomes; D010714:Phosphatidylethanolamines; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C035104:muramylNAc-Ala-isoGln-Lys-tripeptide